9.63
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Is Syndax Pharmaceuticals Inc. a good long term investmentRecord-setting profit potential - PrintWeekIndia
What analysts say about Syndax Pharmaceuticals Inc. stockRapid market gains - PrintWeekIndia
Should I buy Syndax Pharmaceuticals Inc. stock before earningsGame-changing capital returns - jammulinksnews.com
What drives Syndax Pharmaceuticals Inc. stock priceDynamic capital growth - PrintWeekIndia
Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613 - TipRanks
Syndax Pharmaceuticals Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares - MarketBeat
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $69,990.86 in Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Teacher Retirement System of Texas - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.10 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group - MarketBeat
Top Executives at Syndax Pharmaceuticals Make Significant Stock Moves! - TipRanks
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc. stock a good hedge against inflationFree Insider Trading Tips - Newser
Will Syndax Pharmaceuticals Inc. stock benefit from interest rate changesBreakout Confirmation Tool - Newser
(SNDX) Trading Advice - news.stocktradersdaily.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% Following Analyst Downgrade - MarketBeat
UBS Group Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% on Analyst Downgrade - Defense World
Syndax CFO and CEO sell shares at $9.29/share on July 16, 2025. - AInvest
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML - MSN
Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser
What makes Syndax Pharmaceuticals Inc. stock price move sharplyPro Trader Stock Focus - Newser
UBS Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $35 - GuruFocus
자본화:
|
볼륨(24시간):